Ireland - English - HPRA (Health Products Regulatory Authority)

pfizer healthcare ireland - voriconazole - powder for solution for infusion - 200 milligram(s) - triazole derivatives; voriconazole

Ireland - English - HPRA (Health Products Regulatory Authority)

rowex ltd - voriconazole - powder for solution for infusion - 200 milligram(s) - triazole derivatives; voriconazole

European Union - English - EMA (European Medicines Agency)

zoetis belgium sa - maropitant citrate - alimentary tract and metabolism - dogs; cats - tablets dogs:for the prevention of nausea induced by chemotherapy.for the prevention of vomiting induced by motion sickness.for the prevention and treatment of vomiting, in conjunction with cerenia solution for injection and in combination with other supportive measures.solution for injectiondogs:for the treatment and prevention of nausea induced by chemotherapy.for the prevention of vomiting except that induced by motion sickness.for the treatment of vomiting, in combination with other supportive measures.for the prevention of perioperative nausea and vomiting and improvement in recovery from general anaesthesia after use of the μ-opiate receptor agonist morphine.cats:for the prevention of vomiting and the reduction of nausea, except that induced by motion sickness.for the treatment of vomiting, in combination with other supportive measures.

European Union - English - EMA (European Medicines Agency)

hikma farmaceutica (portugal) s.a. - voriconazole - bacterial infections and mycoses; aspergillosis; candidiasis - antimycotics for systemic use - voriconazole is a broad spectrum, triazole antifungal agent and is indicated in adults and children aged 2 years and above as follows:treatment of invasive aspergillosis;treatment of candidaemia in non-neutropenic patients;treatment of fluconazole-resistant serious invasive candida infections (including c. krusei);treatment of serious fungal infections caused by scedosporium spp. and fusarium spp.voriconazole should be administered primarily to patients with progressive, possibly life-threatening infections.prophylaxis of invasive fungal infections in high risk allogeneic hematopoietic stem cell transplant (hsct)recipients.

New Zealand - English - Medsafe (Medicines Safety Authority)

merck sharp & dohme (new zealand) limited - posaconazole 18 mg/ml;   - concentrate for injection - 300mg/16.7ml - active: posaconazole 18 mg/ml   excipient: disodium edetate hydrochloric acid sodium hydroxide sulfobutyl betadex sodium water for injection - noxafil (posaconazole) concentrated injection is indicated for use in the treatment of the following invasive fungal infections in adults: - invasive aspergillosis in patients intolerant of, or with disease that is refractory to, alternative therapy. - fusariosis, zygomycosis, coccidioidomycosis, chromoblastomycosis, and mycetoma in patients intolerant of, or with disease that is refractory to, alternative therapy. noxafil is also indicated for the: - prophylaxis of invasive fungal infections among adults, who are at high risk of developing these infections, such as patients with prolonged neutropenia or haematopoietic stem cell transplant (hsct) recipients.

New Zealand - English - Medsafe (Medicines Safety Authority)

viatris limited - voriconazole 200mg;  ;   - film coated tablet - 200 mg - active: voriconazole 200mg     excipient: croscarmellose sodium lactose monohydrate magnesium stearate opadry white povidone pregelatinised maize starch - vttack is indicated for treatment of the following fungal infections: · invasive aspergillosis. · serious candida infections (including c. krusei), including oesophageal and systemic candida infections (hepatosplenic candidiasis, disseminated candidiasis, candidaemia). · serious fungal infections caused by scedosporium spp. and fusarium spp. · other serious fungal infections, in patients intolerant of, or refractory to, other therapy.

New Zealand - English - Medsafe (Medicines Safety Authority)

viatris limited - voriconazole 50mg;  ;   - film coated tablet - 50 mg - active: voriconazole 50mg     excipient: croscarmellose sodium lactose monohydrate magnesium stearate opadry white 31k58902 povidone pregelatinised maize starch - vttack is indicated for treatment of the following fungal infections: · invasive aspergillosis. · serious candida infections (including c. krusei), including oesophageal and systemic candida infections (hepatosplenic candidiasis, disseminated candidiasis, candidaemia). · serious fungal infections caused by scedosporium spp. and fusarium spp. · other serious fungal infections, in patients intolerant of, or refractory to, other therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

merck sharp & dohme (australia) pty ltd - posaconazole, quantity: 300 mg - injection, concentrated - excipient ingredients: sulfobutyl betadex sodium; disodium edetate; hydrochloric acid; sodium hydroxide; water for injections - noxafil (posaconazole) concentrated injection is indicated for use in the treatment of the following invasive fungal infections in adults: invasive aspergillosis in patients intolerant of, or with disease that is refractory to, alternative therapy. fusariosis, zygomycosis, coccidioidomycosis, chromoblastomycosis, and mycetoma in patients intolerant of, or with disease that is refractory to, alternative therapy. noxafil is also indicated for the: prophylaxis of invasive fungal infections among adults, who are at high risk of developing these infections, such as patients with prolonged neutropenia or haematopoietic stem cell transplant (hsct) recipients.

Australia - English - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - voriconazole -

Australia - English - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - voriconazole -